Date: 2018-01-08

Type of information: Nomination

Compound: chief scientific officer

Company: Innate Pharma (France)

Therapeutic area: Cancer - Oncology - Immunological diseases

Type agreement: nomination

Action mechanism:



  • • On January 8, 2018, Innate Pharma announced that Professor Eric Vivier has joined the company as chief scientific officer (CSO) and senior vice president. Eric Vivier is currently Professor of Immunology at Aix-Marseille University and the Marseille Public Hospitals. He is an international leading authority in the field of immunology. In particular, his research was instrumental in identifying the mechanisms underlying the development and function of Natural Killer (NK) cells as well as in the discovery of innate lymphocyte cells (ILCs). He is the author of more than 300 publications in immunology and ranks among the world’s most cited researchers. He is also one of the founders of Marseille Immunopole, an immunology cluster that integrates fundamental research, therapeutic innovation and industrial development to accelerate the rise of immunotherapy and to make these innovative therapies more easily accessible for patients.
  • In his new role, Professor Vivier will lead Innate Pharma Research Laboratories, which gathers four departments and focuses on target discovery, exploration of mechanism of action, translational research and drug-candidate development. Innate Pharma Research Laboratories relies on the expertise of the Company’s highly experienced researchers and engineers, and its cutting-edge technology platforms. It will also lead the development of collaborations between fundamental, translational and clinical research, particularly working with the Marseille Immunopole ecosystem.

Financial terms:

Latest news:

Is general: Yes